DK1296705T3 - Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom - Google Patents
Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdomInfo
- Publication number
- DK1296705T3 DK1296705T3 DK01947033.5T DK01947033T DK1296705T3 DK 1296705 T3 DK1296705 T3 DK 1296705T3 DK 01947033 T DK01947033 T DK 01947033T DK 1296705 T3 DK1296705 T3 DK 1296705T3
- Authority
- DK
- Denmark
- Prior art keywords
- alleviation
- alzheimer
- beta
- disease
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21477900P | 2000-06-28 | 2000-06-28 | |
| US24217700P | 2000-10-23 | 2000-10-23 | |
| PCT/AU2001/000786 WO2002000245A1 (en) | 2000-06-28 | 2001-06-28 | Neurotoxic oligomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1296705T3 true DK1296705T3 (da) | 2012-09-17 |
Family
ID=26909346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01947033.5T DK1296705T3 (da) | 2000-06-28 | 2001-06-28 | Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7618634B2 (https=) |
| EP (1) | EP1296705B1 (https=) |
| JP (1) | JP2004501204A (https=) |
| CN (2) | CN1450908A (https=) |
| AU (2) | AU6882801A (https=) |
| CA (1) | CA2413354C (https=) |
| DK (1) | DK1296705T3 (https=) |
| ES (1) | ES2389811T3 (https=) |
| NZ (1) | NZ523428A (https=) |
| WO (1) | WO2002000245A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2006014638A2 (en) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| US9335331B2 (en) * | 2005-04-11 | 2016-05-10 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| DK1984344T3 (da) | 2005-12-29 | 2013-01-14 | Lexicon Pharmaceuticals Inc | Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf |
| US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2011064225A1 (en) * | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment |
| JP2013521233A (ja) | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| KR102759003B1 (ko) * | 2018-05-15 | 2025-01-23 | 보오슈 앤드 롬 인코포레이팃드 | 수 추출 가능한 안과용 디바이스 |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| DE102019129221B4 (de) | 2019-10-29 | 2022-05-12 | Chiracon Gmbh | Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN117024554A (zh) * | 2023-05-30 | 2023-11-10 | 中国人民解放军空军军医大学 | 一种Aβ1-42寡聚体存储液的制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-28 ES ES01947033T patent/ES2389811T3/es not_active Expired - Lifetime
- 2001-06-28 JP JP2002505026A patent/JP2004501204A/ja active Pending
- 2001-06-28 EP EP01947033A patent/EP1296705B1/en not_active Expired - Lifetime
- 2001-06-28 DK DK01947033.5T patent/DK1296705T3/da active
- 2001-06-28 NZ NZ523428A patent/NZ523428A/en not_active IP Right Cessation
- 2001-06-28 CN CN01813312A patent/CN1450908A/zh active Pending
- 2001-06-28 US US10/312,437 patent/US7618634B2/en not_active Expired - Fee Related
- 2001-06-28 CN CN2008101298934A patent/CN101411876B/zh not_active Expired - Fee Related
- 2001-06-28 WO PCT/AU2001/000786 patent/WO2002000245A1/en not_active Ceased
- 2001-06-28 AU AU6882801A patent/AU6882801A/xx active Pending
- 2001-06-28 CA CA2413354A patent/CA2413354C/en not_active Expired - Fee Related
- 2001-06-28 AU AU2001268828A patent/AU2001268828C1/en not_active Ceased
-
2009
- 2009-05-14 US US12/466,094 patent/US8318171B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1296705A4 (en) | 2005-04-20 |
| EP1296705B1 (en) | 2012-06-13 |
| US20040013680A1 (en) | 2004-01-22 |
| JP2004501204A (ja) | 2004-01-15 |
| CA2413354A1 (en) | 2002-01-03 |
| NZ523428A (en) | 2008-03-28 |
| CN1450908A (zh) | 2003-10-22 |
| HK1131745A1 (en) | 2010-02-05 |
| CA2413354C (en) | 2014-04-01 |
| AU6882801A (en) | 2002-01-08 |
| US7618634B2 (en) | 2009-11-17 |
| AU2001268828B2 (en) | 2006-07-06 |
| CN101411876A (zh) | 2009-04-22 |
| AU2001268828C1 (en) | 2006-12-14 |
| US20090297538A1 (en) | 2009-12-03 |
| WO2002000245A1 (en) | 2002-01-03 |
| ES2389811T3 (es) | 2012-10-31 |
| US8318171B2 (en) | 2012-11-27 |
| CN101411876B (zh) | 2013-01-16 |
| EP1296705A1 (en) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1296705T3 (da) | Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom | |
| DK1392287T3 (da) | Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom | |
| ZA200300712B (en) | Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome. | |
| IS6560A (is) | Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni | |
| ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
| ATE276244T1 (de) | Replikationsinhibitoren des respiratorischen synzytialvirus | |
| DK1594833T3 (da) | 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme | |
| DE60132851D1 (de) | Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| DK1265577T3 (da) | Medicinsk eller dentalmedicinsk behandlingsstol | |
| NO20020156D0 (no) | Titanavledede forbindelser, fremstilling og anvendelse derav | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| FR2805456B1 (fr) | Prothese totale de genou, du type dit "postero-stabilisee" | |
| NO20040659D0 (no) | Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom | |
| DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
| FR2810540B1 (fr) | Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion | |
| NO20032597D0 (no) | Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma | |
| NO20024746L (no) | Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom | |
| ITRM20000556A0 (it) | S-adenosilmetionina e suoi derivati per il trattamento e la prevenzione della malattia di alzheimer. | |
| IL150527A0 (en) | Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives | |
| PT1408035E (pt) | Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros | |
| ITRM20000106A0 (it) | Composizione per la prevenzione e/o il trattamento di vascolopatie, che comprende propionil l-carnitina e coenzima q10. | |
| DK1152762T3 (da) | Anvendelse af desoxypeganin til behandling af Alzheimers demens | |
| ES1047413Y (es) | Bolsa protectora de racimos de uva en la propia cepa. | |
| IT1310374B1 (it) | Teca per l'esposizione in sicurezza di oggetti. |